DLM: Vitamin E (2001)
The ADA 2001 Hyperlipidemia MNT Evidence-based guide for practice was originally published in a compact disk (CD) format. This 2001 project was published to the online Evidence Analysis Library for the benefit of ADA members, even though it does not follow the current online format and may be missing some of the components (all of the components of current evidence analysis include: question, conclusion, grade, search plan and results, evidence summary, overview table, worksheets, and quality check lists.)
Vitamin E (Hyperlipidemia 2001)
Vitamin E intake has been associated with decreased risk for cardiovascular death and nonfatal MI in observational studies (cohort and cross-sectional) and nonfatal MI in one RCT (CHAOS) in subjects with CAD. However, three other RCT using 400 IU/d of vitamin E supplementaion for 4 to 5 years had no impact on the incidence of non-fatal or fatal CHD.
This information is from the 2001 Hyperlipidemia project.
- Grade I means there is Good/Strong evidence supporting the statement;
- Grade II is Fair;
- Grade III is Limited/Weak;
- Grade IV is Expert Opinion Only;
- Grade V is Not Assignable.
Evidence Summary: Vitamin E (Hyperlipidemia 2001)
- Quality Rating Summary
For a summary of the Quality Rating results, click here.
- Davey PJ, Schulz M, Gliksman M, Dobson M, Aristides M, Stephens NG. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS Trial). Am J Cardiology. 1998.
- Diaz MN, Frei B, Vita J, Keaney J. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997; 337: 408-416.
- Emmert DH, Kirchner JT. The role of vitamin E in the prevention of heart disease. Arch Fam Med. 1999; 8: 537-542.
- Gissi-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet. 1999; 354: 447-455.
- Hodis HN, Mack WJ, LaBree L, Cashin OHemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 1995; 273: 1849-1854.
- Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick R. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996; 334: 1156-1162.
- Lonn E. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and the MICRO-HOPE substudy. Diabetes Care. 2002; 25: 1,919-1,927.
- Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary disease in men. NEJM. 1993; 328: 1,450-1,456.
- Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. New Engl J Med. 1993; 328: 1444-1449.
- Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet, 1996; 347: 781-786.
- Tribble DL. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and beta-carotene. Circulation. 1999; 99: 591-595.